Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data

Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being...

Descripción completa

Detalles Bibliográficos
Autores principales: Roex, Gils, Feys, Tom, Beguin, Yves, Kerre, Tessa, Poiré, Xavier, Lewalle, Philippe, Vandenberghe, Peter, Bron, Dominique, Anguille, Sébastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076393/
https://www.ncbi.nlm.nih.gov/pubmed/32102267
http://dx.doi.org/10.3390/pharmaceutics12020194
_version_ 1783507206235226112
author Roex, Gils
Feys, Tom
Beguin, Yves
Kerre, Tessa
Poiré, Xavier
Lewalle, Philippe
Vandenberghe, Peter
Bron, Dominique
Anguille, Sébastien
author_facet Roex, Gils
Feys, Tom
Beguin, Yves
Kerre, Tessa
Poiré, Xavier
Lewalle, Philippe
Vandenberghe, Peter
Bron, Dominique
Anguille, Sébastien
author_sort Roex, Gils
collection PubMed
description Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.
format Online
Article
Text
id pubmed-7076393
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70763932020-03-24 Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data Roex, Gils Feys, Tom Beguin, Yves Kerre, Tessa Poiré, Xavier Lewalle, Philippe Vandenberghe, Peter Bron, Dominique Anguille, Sébastien Pharmaceutics Review Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively. MDPI 2020-02-24 /pmc/articles/PMC7076393/ /pubmed/32102267 http://dx.doi.org/10.3390/pharmaceutics12020194 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Roex, Gils
Feys, Tom
Beguin, Yves
Kerre, Tessa
Poiré, Xavier
Lewalle, Philippe
Vandenberghe, Peter
Bron, Dominique
Anguille, Sébastien
Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
title Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
title_full Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
title_fullStr Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
title_full_unstemmed Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
title_short Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
title_sort chimeric antigen receptor-t-cell therapy for b-cell hematological malignancies: an update of the pivotal clinical trial data
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076393/
https://www.ncbi.nlm.nih.gov/pubmed/32102267
http://dx.doi.org/10.3390/pharmaceutics12020194
work_keys_str_mv AT roexgils chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata
AT feystom chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata
AT beguinyves chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata
AT kerretessa chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata
AT poirexavier chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata
AT lewallephilippe chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata
AT vandenberghepeter chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata
AT brondominique chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata
AT anguillesebastien chimericantigenreceptortcelltherapyforbcellhematologicalmalignanciesanupdateofthepivotalclinicaltrialdata

Ejemplares similares